https://scholars.lib.ntu.edu.tw/handle/123456789/568363
標題: | Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update | 作者: | Omata M. ANN-LII CHENG Kokudo N. Kudo M. Lee J.M. Jia J. Tateishi R. Han K.-H. Chawla Y.K. Shiina S. Jafri W. Payawal D.A. Ohki T. Ogasawara S. PEI-JER CHEN Lesmana C.R.A. Lesmana L.A. Gani R.A. Obi S. Dokmeci A.K. Sarin S.K. |
公開日期: | 2017 | 出版社: | Springer India | 卷: | 11 | 期: | 4 | 起(迄)頁: | 317-370 | 來源出版物: | Hepatology International | 摘要: | There is great geographical variation in the distribution of hepatocellular carcinoma (HCC), with the majority of all cases worldwide found in the Asia–Pacific region, where HCC is one of the leading public health problems. Since the “Toward Revision of the Asian Pacific Association for the Study of the Liver (APASL) HCC Guidelines” meeting held at the 25th annual conference of the APASL in Tokyo, the newest guidelines for the treatment of HCC published by the APASL has been discussed. This latest guidelines recommend evidence-based management of HCC and are considered suitable for universal use in the Asia–Pacific region, which has a diversity of medical environments. ? 2017, The Author(s). |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85020518973&doi=10.1007%2fs12072-017-9799-9&partnerID=40&md5=3bb12d3acfcf1f9c5812dab65a0c97fb https://scholars.lib.ntu.edu.tw/handle/123456789/568363 |
ISSN: | 1936-0533 | DOI: | 10.1007/s12072-017-9799-9 | SDG/關鍵字: | adefovir; aflatoxin B1; agglutinin; alpha fetoprotein; alpha levo fucosidase; alpha2b interferon; decarboxyprothrombin; durvalumab; entecavir; gadoxetic acid; galunisertib; glypican 3; hepatitis B vaccine; ipilimumab; lamivudine; meloxicam; menaquinone; menatetrenone; nivolumab; pembrolizumab; peretinoin; placebo; ramucirumab; regorafenib; retinoid; sorafenib; ticilimumab; tumor marker; UFT; unindexed drug; alcohol consumption; algorithm; Australia; Budd Chiari syndrome; cancer epidemiology; cancer immunotherapy; cancer incidence; cancer prevention; cancer risk; cancer screening; chemoembolization; China; clinical practice; coffee; computer assisted tomography; contrast enhancement; diffusion weighted imaging; drug efficacy; echography; Editorial; evidence based medicine; hepatitis B; hepatitis C; Hong Kong; human; India; infection prevention; intermethod comparison; Iran; Japan; Korea; lentil; liver arteriography; liver cell carcinoma; liver cirrhosis; liver resection; liver transplantation; medical decision making; metabolic syndrome X; mixed infection; molecularly targeted therapy; Mongolia; multiple cycle treatment; New Zealand; nonalcoholic fatty liver; overall survival; Pakistan; physician attitude; practice guideline; primary prevention; priority journal; radiation injury; radiofrequency ablation; recurrence free survival; risk assessment; stereotactic body radiation therapy; survival rate; Taiwan; tea; tertiary prevention; tobacco; treatment contraindication; treatment indication; treatment response; vaccination; Viet Nam; virus hepatitis; Asia; Carcinoma, Hepatocellular; Coinfection; disease management; hepatitis B; hepatitis C; Liver Neoplasms; meta analysis (topic); virology; Asia; Carcinoma, Hepatocellular; Coinfection; Disease Management; Evidence-Based Medicine; Hepatitis B; Hepatitis C; Humans; Liver Neoplasms; Meta-Analysis as Topic; Practice Guidelines as Topic |
顯示於: | 臨床醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。